ABSTRACT BACKGROUND The optimal treatment strategy when combining antiplatelets with oral anticoagulants in patients
with standard dosage VKAs. The study was limited by using dosages that are not approved for stroke prophylaxis in AF, and the risk of bleeding when using recommended dosages remains therefore unknown (14) . The aim of our study was to investigate the comparative risk of bleeding, ischemic stroke, MI, and all-cause mortality during treatment with DOACs or VKAs, and concomitant use of aspirin, clopidogrel, or both, in patients with AF following MI and/or PCI.
METHODS
DATASETS. Danish nationwide administrative registries were used (16) (17) (18) . A personal identification number is given to every (aspirin and/or clopidogrel) 7 days after a hospital discharge with an MI, PCI, or both. Patients below 30 years of age or above 100 years were excluded, as were patients with valvular AF. The inclusion date was defined as 7 days after discharge with an MI, PCI, or both, thus providing a quarantine period of 7 days.
A quarantine period was introduced to allow patients to collect a prescription from a pharmacy and also to minimize the risk of registering complications that were related to the hospitalization. Patients who died or experienced 1 of the pre-defined outcomes (bleeding, ischemic stroke, or MI) during the quarantine period were also excluded. Table 1 ).
From the Danish National Prescription Registry, concomitant medication was identified from claimed prescriptions up to 180 days before the inclusion date, using ATC codes (Online Table 1 ).
The CHA 2 DS 2 -VASc score was used to assess the risk of stroke, and a modified HAS-BLED score was used to assess the risk of bleeding, Labile international normalized ratio (INR) was not available in our data and use of antiplatelets was the exposure variable in our study, hence, these were not included in the calculation of the modified HAS-BLED score. and VKAþDAPT was compared with DOACþDAPT. All analyses were performed on an intention-to-treat basis. Groups containing VKA were used as a reference. Death was considered a competing risk for the outcomes of MI, stroke, and bleeding (23) . All models were adjusted for inclusion event (MI and/or PCI), age, sex, calendar year. Variables in the modified HAS-BLED for the bleeding outcomes were used for the models for bleeding because the score has been found valid to predict the risk of bleeding in atrial fibrillation patients (24, 25) . The models for ischemic stroke, MI, and all-cause mortality were adjusted for risk factors incorporated in the CHA 2 DS 2 -VASc score, because stroke and MI share many of the same risk factors (26, 27) . In addition, the CHA 2 DS 2 -VASc score has been found to also correlate well with mortality (26, 27) .
Absolute risk of each of the outcomes was calculated on the basis of multiple outcome-specific Cox regression models, whereby average treatment effects between the groups could be obtained as standardized differences in absolute risks at 3 and 12 months. This was done using the g-formula, and 95% confidence intervals (CIs) based on 1,000 bootstrap samples were obtained (28) . Patients were followed for 12 months or until an event, death, immigration, or 30th June 2017.
All models were tested for significant interactions with age, sex, DOAC dosage, and proton pump Compared with VKAþDAPT, DOACþDAPT was Figure 2 ). Likewise, no significant difference was found between
VKAþSAPT and DOACþSAPT (ARD: À0.51%, 95% CI:
À1.50% to 0.33%) ( Table 2 , Figure 3 ). Similar associations were found for the 12-month absolute risks. However, no significant difference was found between
VKAþSAPT and DOACþSAPT (ARD: 0.47%, CI: À0.74% to 2.08%) (Table 2, Figure 3 ). Similar associations were found for the 12-months absolute risks.
SENSITIVITY AND SUBGROUP ANALYSES. The analyses using the exposure to any of the antithrombotic regimens as a time dependent variable showed similar results as the main results with regard to allcause mortality, bleeding, ischemic stroke, and MI (Table 3) . Furthermore, baseline characteristics (Online Table 3 ) when stratifying on the basis of DOAC dosage (reduced or standard dosage) showed that patients initiated on reduced dosage DOAC were older, less often had PCI, had more heart failure, and had chronic kidney disease, which resulted in these patients having a higher HAS-BLED score. In all subgroup analyses regarding dosages, results were comparable to the main analyses (Online Tables 4 and 5 ). In addition, we compared VKAþSAPT with VKAþDAPT, and likewise for the DOAC groups, where it was found Values are n (%) or mean (interquartile range).
COPD ¼ chronic obstructive pulmonary disease; DAPT ¼ dual antiplatelet therapy (aspirinþclopidogrel); DOAC ¼ direct oral anticoagulant; MI ¼ Myocardial infarction; NSAID ¼ non-steroidal anti-inflammatory drug; PCI ¼ percutaneous coronary intervention; PPI ¼ proton pump inhibitor; RAS ¼ renin angiotensin system blocker; SAPT ¼ single antiplatelet therapy (aspirin or clopidogrel); VKA ¼ vitamin K antagonist.
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that VKAþDAPT was associated with a 2-fold increased risk of bleeding compared with VKAþSAPT (Online Table 6 ).
DISCUSSION
The main results of this study were: 1) compared with VKAþDAPT, DOACþDAPT was associated with a significantly decreased risk of bleeding; 2) no significant differences in the risk of ischemic stroke, MI, or all-cause mortality was found between VKAþDAPT and DOACþDAPT; and 3) no significant differences in the risk of bleeding, ischemic stroke, or all-cause mortality were found between VKAþSAPT versus DOACþSAPT, but a significantly decreased risk of MI was found to be associated with DOACþSAPT (Central Illustration). Statistical significance is reached, when the 95% confidence interval for the absolute risk difference does not include 0. Bold indicates that the absolute risk difference is significant. *Adjusted for sex, age, calendar year, inclusion event, heart failure, hypertension, diabetes, prior stroke, vascular disease, prior bleeding, liver disease, chronic kidney disease, alcohol abuse, and non-steroidal anti-inflammatory drugs. †Adjusted for sex, age, calendar year, inclusion event, heart failure, hypertension, diabetes, prior stroke, and vascular disease.
CI ¼ confidence interval; other abbreviations as in Table 1 . Ref.
Outcome-specific hazard ratios in patients treated with DOAC or VKA in combination with aspirin and clopidogrel. *Adjusted for sex, age, calendar year, inclusion event, and factors incorporated the CHA 2 DS 2 -VASc score. †Adjusted for sex, age, calendar year, inclusion event, and factors incorporated in the HAS-BLED score. CI ¼ confidence interval; HR ¼ hazard ratio; other abbreviations as in Figure 1 .
Sindet-Pedersen et al. Comparable to the WOEST and REDUAL-PCI trials, our study found VKAþSAPT to be associated with a significantly reduced risk of bleeding compared with VKAþDAPT. It was noteworthy that the absolute risks of MI, stroke, and all-cause mortality were higher for patients treated with VKAþSAPT compared with VKAþDAPT in our study. This may be explained by differences in age and comorbidities between the groups, and thus, after adjustments in the models, the results did not reach statistical significance.
STUDY STRENGTHS AND LIMITATIONS. Several strengths regarding our study should be mentioned. 
